All In Biotech

Drug Trial Radar · NCT05406999

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

A Prospective, Multi-arm, Multi-center Clinical Trial on Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Aug 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Feb 1, 2020

Primary completion

Dec 31, 2026

Study completion Jun 30, 2030

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jun 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.

Conditions

  • Neoadjuvant Therapy
  • High Risk Prostate Cancer
  • Locally Advanced Prostate Cancer
  • Intense Endocrine Therapy

Interventions

  • ADTDrug

    The ADT regimen will be determined by the investigators at separate centers. The dose and frequency of administration will be consistent with the prescribing information. Available drugs include triptorelin, goserelin, leuprolide, digareke ect.

  • Abiraterone AcetateDrug

    1000 mg (250 mg×4 tablets) once daily, orally

  • Prednisolone tabletsDrug

    5 mg once daily, orally.

  • EnzalutamideDrug

    160 mg (40 mg× 4 tablets) once daily, orally.

  • ApalutamideDrug

    240 mg (60 mg×4 tablets) once daily, orally.

  • DarotamideDrug

    600 mg (300 mg × 2 tablets) twice daily, orally.

  • RezvilutamideDrug

    240 mg (80 mg × 3 tablets) once daily orally

  • PARP inhibitorDrug

    The PARP inhibitors will be determined by the investigators at separate centers. The dosage and frequency of administration will be consistent with the prescribing information. Available drugs include olaparib, fluzoparib, pamiparib, talazoparib ect.

  • Robot-assisted radical prostatectomyProcedure

    Robot-assisted radical prostatectomy was performed within 2 weeks after the end of the therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pathologic response rateTime frame: up to 3 years
  2. 3 year biochemical progression free survival (bPFS)Time frame: up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.